Rapport Therapeutics (NASDAQ:RAPP) Given Buy Rating at HC Wainwright

Rapport Therapeutics (NASDAQ:RAPP)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Tuesday, Marketbeat Ratings reports. They presently have a $66.00 price target on the stock. HC Wainwright‘s price target indicates a potential upside of 124.72% from the company’s previous close.

Several other research analysts have also weighed in on the company. Wolfe Research assumed coverage on Rapport Therapeutics in a research report on Thursday, October 15th. They issued an “outperform” rating and a $50.00 target price on the stock. Wall Street Zen lowered Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. TD Cowen reaffirmed a “buy” rating on shares of Rapport Therapeutics in a research report on Tuesday. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Rapport Therapeutics in a research report on Tuesday, September 22nd. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Rapport Therapeutics in a research report on Wednesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $66.10.

Rapport Therapeutics Stock Performance

Shares of RAPP traded up $0.77 during trading hours on Tuesday, hitting $29.37. The stock had a trading volume of 8,191,152 shares, compared to its average volume of 393,051. The firm has a market cap of $1.41 billion, a P/E ratio of -9.66 and a beta of 1.22. The company’s fifty day simple moving average is $40.70 and its 200 day simple moving average is $39.14. Rapport Therapeutics has a 12-month low of $23.75 and a 12-month high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP) last issued its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, sell-side analysts predict that Rapport Therapeutics will post -4.09 earnings per share for the current fiscal year.

Insider Buying and Selling at Rapport Therapeutics

In related news, COO Cheryl Gault sold 10,000 shares of the stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $33.19, for a total value of $331,900.00. Following the completion of the sale, the chief operating officer directly owned 139,914 shares in the company, valued at approximately $4,643,745.66. This represents a 6.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Abraham Ceesay sold 1,147 shares of the stock in a transaction on Wednesday, October 7th. The shares were sold at an average price of $30.66, for a total value of $35,167.02. Following the completion of the sale, the chief executive officer owned 452,245 shares of the company’s stock, valued at approximately $13,865,831.70. This represents a 0.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 97,976 shares of company stock valued at $4,420,349. 12.48% of the stock is owned by insiders.

Institutional Trading of Rapport Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Algert Global LLC acquired a new stake in shares of Rapport Therapeutics during the second quarter valued at about $9,327,000. Johnson & Johnson acquired a new stake in shares of Rapport Therapeutics during the second quarter valued at about $74,360,823. Legal & General Group Plc acquired a new stake in shares of Rapport Therapeutics during the second quarter valued at about $940,000. Walleye Capital LLC acquired a new stake in shares of Rapport Therapeutics during the second quarter valued at about $4,257,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Rapport Therapeutics during the second quarter valued at about $3,426,000.

Key Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 endpoints. The trial showed statistically significant placebo-adjusted improvements at Week 3 in the Young Mania Rating Scale total score of 3.1 points (p=0.045) and the CGI-BP Severity of Mania score of 0.4 points (p=0.024). The data support further development of RAP-219 and helped drive substantial premarket interest. Rapport Therapeutics Announces Positive Topline Results
• Positive Sentiment: Analysts raised their expectations following the trial readout. BTIG Research increased its price target from $75 to $89 and maintained a Buy rating, while HC Wainwright reaffirmed its Buy rating with a $66 target. Jefferies reportedly estimates RAP-219 could become a $1 billion peak-sales product if successfully developed and commercialized. Inside the $1 Billion Blockbuster Opportunity
• Positive Sentiment: Trading activity surged. Premarket volume was reported at roughly 1.4 million shares, well above the stock’s typical daily volume, indicating strong investor attention and positioning around the clinical update. Why Is Rapport Therapeutics Stock Trading Higher Today?
• Neutral Sentiment: Wells Fargo continued to rate RAPP Buy, adding to the favorable analyst sentiment but offering no new clinical or financial information. Wells Fargo Sticks to Its Buy Rating
• Negative Sentiment: The clinical win was not viewed as unequivocally strong. Coverage described the benefit as narrowly meeting statistical thresholds and falling short of the trial’s original ambition, leaving questions about the magnitude and durability of RAP-219’s advantage. Rapport’s Phase 2 Bipolar Data
• Negative Sentiment: Investors remain sensitive to valuation and execution risk after a steep recent monthly decline, ongoing losses, and a prior quarterly EPS miss. Rapport Therapeutics Stock Seems Pricey

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its proprietary RAP platform to identify and target synaptic receptor-associated proteins, which can influence the activity, distribution and function of receptors involved in the central nervous system.

Rapport’s lead clinical program is relutrigine, also known as RAP-219, an orally administered small-molecule therapy being developed for focal epilepsy.